Skip to main content

Revision to Kalydeco Clinical Prior Authorization Coming December 28, 2020

Last updated on

On September 25, 2020, the U.S. Food and Drug Administration approved Kalydeco (ivacaftor) to treat children four months through six months of age with cystic fibrosis who have one mutation cystic fibrosis transmembrane conductance regulator gene responsive to ivacaftor. Kalydeco was already approved for children aged six months and older.

Beginning December 28, 2020, Medicaid will revise the Kalydeco clinical prior authorization criteria to allow children four months of age and older to meet the gene mutation approval criteria to receive treatment.

Email VDP-Formulary@hhsc.state.tx.us with questions or comments.